
Pulled from Benzinga Pro data, Mirum Pharmaceuticals (NASDAQ:MIRM) posted Q4 earnings of $57.55 million, an increase from Q3 of 222.16%. Sales dropped to $3.14 million, a 37.24% decrease between quarters. In Q3, Mirum Pharmaceuticals brought in $5.00 million in sales but lost $47.11 million in earnings.